Dr. Glaucomflecken wants the corporatization of medicine to be national news
-
By
-
Torie Bosch
-
May 9, 2026
By
Torie Bosch
May 9, 2026
by Torie Bosch
May 9, 2026
Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease
May 8, 2026
Retrospective study investigates links between acute ischemic ocular events and increased stroke risk
May 8, 2026
Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven
by Kerri Miller
May 7, 2026